What question did this study set out to answer?

This study aims to establish the conditions under which patients with chronic myeloid leukemia can safely discontinue treatment and predict outcomes.

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial defines conditions for treatment discontinuation in chronic myeloid leukemia, indicating safe monitoring strategies.

This study aims to establish the conditions under which patients with chronic myeloid leukemia can safely discontinue treatment and predict outcomes.
Collected data from 802 cases of tyrosine kinase inhibitor discontinuation across 11 centers.
Focused on patients with chronic myeloid leukemia who maintained a deep molecular response for at least two years.
Developed predictive models and a web-based calculator for clinical decision-making.
318 out of 698 eligible patients (45.6%) lost major molecular response within 12 months, mostly in the first 6 months.
TFR rates were 66.5% at 6 months, 57.7% at 12 months, and 55.5% at 24 months after discontinuation.
Patients with longer TKI treatment duration and sustained deep molecular responses had higher TFR rates, validated by predictive models.

Cheng et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial defines conditions for treatment discontinuation in chronic myeloid leukemia, indicating safe monitoring strategies.

This study aims to establish the conditions under which patients with chronic myeloid leukemia can safely discontinue treatment and predict outcomes.
Collected data from 802 cases of tyrosine kinase inhibitor discontinuation across 11 centers.
Focused on patients with chronic myeloid leukemia who maintained a deep molecular response for at least two years.
Developed predictive models and a web-based calculator for clinical decision-making.
318 out of 698 eligible patients (45.6%) lost major molecular response within 12 months, mostly in the first 6 months.
TFR rates were 66.5% at 6 months, 57.7% at 12 months, and 55.5% at 24 months after discontinuation.
Patients with longer TKI treatment duration and sustained deep molecular responses had higher TFR rates, validated by predictive models.

Cheng et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark